Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety

Overview of attention for article published in BMC Cancer, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 1,020 followers.

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety https://t.co/oDDK0A2GPF https://t.co/VaLwCmDmRA

New article: Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety https://t.co/HFm9aIOCTs #livercancer #oncology https://t.co/mIUtUoJY4N

New article: Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety https://t.co/ua9d1vapa2 #breastcancer #oncology https://t.co/7hFDyAv1wu

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.